Who should consider genetic counseling & testing?
Genetic counseling and testing for BRCA 1 and BRCA 2 mutations should be considered if you meet any ONE of the following criteria*:
The American Society of Clinical Oncology (ASCO) recommends genetic testing for BRCA 1 and BRCA 2 mutations be performed in the setting of both pre-and post test counseling, by an individual specialized in the area of cancer genetics**.
- Family member with a BRCA 1 or BRCA 2 mutation
- Personal history of breast cancer (invasive breast cancer or ductal carcinoma in situ (DCIS))
- Family history of breast cancer
- Personal history of ovarian/fallopian tube/primary peritoneal cancer
- Family history of ovarian/fallopian tube/primary peritoneal cancer
- Personal history of male breast cancer
- Family history of male breast cancer
- Personal history of pancreatic cancer
- Family history of pancreatic cancer
The American Society of Clinical Oncology (ASCO) recommends genetic testing for BRCA 1 and BRCA 2 mutations be performed in the setting of both pre-and post test counseling, by an individual specialized in the area of cancer genetics**.
What is genetic counseling?
Genetic counselors are medical specialists with an advanced degree in genetics earned from an accredited graduate program in genetic counseling. Genetic counselors are certified through a board examination administered by the American Board of Genetic Counseling. Women referred for genetic testing for hereditary breast and ovarian cancer are encouraged to meet with a genetic counselor prior to undergoing testing to learn about the risks, benefits, and limitations of the genetic test.
What is genetic testing?
If you meet specific criteria, a genetic counselor will discuss genetic testing. Women who test positive for a BRCA 1 or a BRCA 2 mutation are counseled in a more personalized manner regarding their increased cancer risks. Based on the mutation identified, as well as a woman’s personal medical history and family history, the patient can be advised by her physician to undergo the appropriate high-risk screening and/or risk-reducing surgeries.
________________________________________________________________________
*Based on criteria from the National Comprehensive Cancer Network-Clinical practice guidelines in oncology genetic/familial high-risk assessment: breast and ovarian. Version 1.2011.
**Robson ME., et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010; 28(5): 839-901.
________________________________________________________________________
*Based on criteria from the National Comprehensive Cancer Network-Clinical practice guidelines in oncology genetic/familial high-risk assessment: breast and ovarian. Version 1.2011.
**Robson ME., et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010; 28(5): 839-901.
